The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas

Abstract Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunothe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kai Li, Lei Ma, Ye Sun, Xiang Li, Hong Ren, Shou-Ching Tang, Xin Sun
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bbf27ca926fd41d7b6bf1a3437ce9d68
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bbf27ca926fd41d7b6bf1a3437ce9d68
record_format	dspace
spelling	oai:doaj.org-article:bbf27ca926fd41d7b6bf1a3437ce9d682021-12-02T17:26:55ZThe immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas10.1038/s41598-021-98131-42045-2322https://doaj.org/article/bbf27ca926fd41d7b6bf1a3437ce9d682021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98131-4https://doaj.org/toc/2045-2322Abstract Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunotherapy outcomes in breast cancer using several public databases. The possible treatment target TNF superfamily member 4 (TNFSF4) was selected from many candidates based on its abnormal expression profile, survival-associated status, and ability to predict immune system reactions. For the first time, we identified the oncogenic features of TNFSF4 in breast carcinoma. TNFSF4 was revealed to be closely related to treatment that induced antitumor immunity and to interact with multiple immune effector molecules and T cell signatures, which was independent of endocrine status and has not been reported previously. Moreover, the potential immunotherapeutic approach of TNFSF4 blockade showed underlying effects on stem cell expansion, which more strongly and specifically demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast carcinomas. We identified potential targets that may contribute to breast cancer therapies through clinical analysis and real-world review and provided one potential but crucial tool for treating breast carcinoma that showed effects across subtypes and long-term effectiveness.Kai LiLei MaYe SunXiang LiHong RenShou-Ching TangXin SunNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kai Li Lei Ma Ye Sun Xiang Li Hong Ren Shou-Ching Tang Xin Sun The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
description	Abstract Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunotherapy outcomes in breast cancer using several public databases. The possible treatment target TNF superfamily member 4 (TNFSF4) was selected from many candidates based on its abnormal expression profile, survival-associated status, and ability to predict immune system reactions. For the first time, we identified the oncogenic features of TNFSF4 in breast carcinoma. TNFSF4 was revealed to be closely related to treatment that induced antitumor immunity and to interact with multiple immune effector molecules and T cell signatures, which was independent of endocrine status and has not been reported previously. Moreover, the potential immunotherapeutic approach of TNFSF4 blockade showed underlying effects on stem cell expansion, which more strongly and specifically demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast carcinomas. We identified potential targets that may contribute to breast cancer therapies through clinical analysis and real-world review and provided one potential but crucial tool for treating breast carcinoma that showed effects across subtypes and long-term effectiveness.
format	article
author	Kai Li Lei Ma Ye Sun Xiang Li Hong Ren Shou-Ching Tang Xin Sun
author_facet	Kai Li Lei Ma Ye Sun Xiang Li Hong Ren Shou-Ching Tang Xin Sun
author_sort	Kai Li
title	The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
title_short	The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
title_full	The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
title_fullStr	The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
title_full_unstemmed	The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
title_sort	immunotherapy candidate tnfsf4 may help the induction of a promising immunological response in breast carcinomas
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bbf27ca926fd41d7b6bf1a3437ce9d68
work_keys_str_mv	AT kaili theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT leima theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT yesun theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xiangli theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT hongren theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT shouchingtang theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xinsun theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT kaili immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT leima immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT yesun immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xiangli immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT hongren immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT shouchingtang immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xinsun immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas
_version_	1718380809989128192

The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas

Ejemplares similares